Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient

about

Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient

Item

http://www.wikidata.org/entity/Q35668667

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Effectiveness of Intravenous I ...... an Kidney Transplant Recipient

@ast

Effectiveness of Intravenous I ...... an Kidney Transplant Recipient

@en

type

Item

label

Effectiveness of Intravenous I ...... an Kidney Transplant Recipient

@ast

Effectiveness of Intravenous I ...... an Kidney Transplant Recipient

@en

prefLabel

Effectiveness of Intravenous I ...... an Kidney Transplant Recipient

@ast

Effectiveness of Intravenous I ...... an Kidney Transplant Recipient

@en

P1476

Effectiveness of Intravenous I ...... an Kidney Transplant Recipient

@en

P2093

Amin Hosni

http://www.w3.org/2001/XMLSchema#string

Atefeh Jafari

http://www.w3.org/2001/XMLSchema#string

Lida Shojaie

http://www.w3.org/2001/XMLSchema#string

Mohammad Reza Khatami

http://www.w3.org/2001/XMLSchema#string

Simin Dashti-Khavidaki

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment options and strategies for antibody mediated rejection after renal transplantation

Survival and relapse in patients with thrombotic thrombocytopenic purpura.

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.

Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange.

Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?

Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.

Syndromes of thrombotic microangiopathy.

Immunoglobulin in the control of complement action.

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Diagnosis and management of antibody-mediated rejection: current status and novel approaches.

P304

e27073

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5812/NUMONTHLY.7(3)2015.27073

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276501364

http://www.w3.org/2001/XMLSchema#string

P698

26034746

http://www.w3.org/2001/XMLSchema#string

P932

4450162

http://www.w3.org/2001/XMLSchema#string